# Lakefront Biotherapeutics NV: Form 20-F for the period ended Dec 31, 2022

- Company: [Lakefront Biotherapeutics NV](/companies/lkft.md) (CIK 1421876)
- Form: 20-F
- Filed: 2023-03-23
- Accepted by EDGAR: Mar 23, 2023, 16:02 ET
- Period: 2022-12-31
- Accession: 0001558370-23-004448
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1421876/000155837023004448/glpg-20221231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1421876/000155837023004448/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2022-01-01 to 2022-12-31 | EUR 505.3m | ifrs-full:Revenue |
| Cost of revenue | 12 months, 2022-01-01 to 2022-12-31 | EUR 12.1m | ifrs-full:CostOfSales |
| Operating income | 12 months, 2022-01-01 to 2022-12-31 | −EUR 267.5m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2022-01-01 to 2022-12-31 | EUR 2.8m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2022-01-01 to 2022-12-31 | −EUR 218.0m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months, 2022-01-01 to 2022-12-31 | −EUR 3.32 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2022-01-01 to 2022-12-31 | −EUR 3.32 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2022-01-01 to 2022-12-31 | −EUR 500.5m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2022-01-01 to 2022-12-31 | EUR 27.4m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2022-12-31 | $97.3m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2022-12-31 | EUR 4.24bn | ifrs-full:CurrentAssets |
| Total assets | at 2022-12-31 | EUR 4.73bn | ifrs-full:Assets |
| Current liabilities | at 2022-12-31 | EUR 522.5m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2022-12-31 | EUR 2.21bn | ifrs-full:Liabilities |
| Shareholders' equity | at 2022-12-31 | EUR 2.53bn | ifrs-full:Equity |
| Shares outstanding | at 2022-12-31 | 65,835,511 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1421876/000155837023004448/glpg-20221231x20f.htm

Filed Mar 23, 2023.
Source: SEC EDGAR, the filing index for accession 0001558370-23-004448. Last ingested by Listed: Nov 4, 2026, 10:00 ET. No prices; not investment advice.